ALPHABET study

Comparison of efficacy and safety of tamsulosin and vibegron for male lower urinary tract symptoms -Multicenter randomized crossover study- - ALPHABET study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1011230058

Enrollment

Registered

2024-01-26

Start date

2024-01-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder with benign prostatic hyperplasia OAB BPH

Interventions

tamusulocin vibegron

alpha blocker, be-ta3agonist

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Age over 40 Prostate volume less than 30ml OAB Postvoid residual less than 100ml Patients who agree with the research

Exclusion criteria

Exclusion criteria: Postvoid residual over 100ml suspected of prostate cancer any medicationfor LUTS within 8 weeks patients with neurogenic disease patients with active urinary infection patients with hypotension patients with severe heart disease patients with severe liver disease pateints with severe kidney disease patients with allergy with tamsulocin/vibegron

Design outcomes

Primary

Measure	Time frame
OABSS	—

Secondary

Measure	Time frame
IPSS postvoid residual	—

Contacts

Public ContactNaoki Wada

Asahikawa Medical University

nwada@asahikawa-med.ac.jp+81-166-68-2533

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026